MKI67 and adenocarcinoma: These findings parallel international data showing that Ki-67 thresholds around 10–15% stratify recurrence risk and survival in both GISTs and adenocarcinomas [10,11,13,22] and that elevated Ki-67 in small bowel adenocarcinomas is linked to nodal spread and poorer prognosis [11].